» Authors » Ji-Lin Cheng

Ji-Lin Cheng

Explore the profile of Ji-Lin Cheng including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 91
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang J, Chen L, Wang Y, Lyu B, Zhao H, Shang Z, et al.
Chin Med J (Engl) . 2020 Jun; 133(14):1639-1648. PMID: 32568867
Background: The efficacy of entecavir (ETV) add-on peg-interferon therapy compared with ETV monotherapy in treatment-naïve hepatitis B virus (HBV) patients remains controversial. We investigated whether adding peg-interferon to ongoing ETV...
2.
Wu S, Liu L, Cheng J, Liu Y, Cheng L, Wang S, et al.
Clin Exp Med . 2018 Apr; 18(3):433-443. PMID: 29696462
The correlation between improvement in longitudinal liver stiffness and fibrosis regression has not been properly evaluated during long-term antiviral therapy in chronic hepatitis B (CHB) patients. In this study, liver...
3.
Cheng Y, Li D, Cheng X, Liu B, Cheng J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi . 2010 Apr; 23(5):321-4. PMID: 20387474
Objective: To explore the distribution of cytomegalovirus (CMV) in vascular tissues and the relationship between virus and atherosclerogenesis after CMV infecting mice. Methods: (1) C57 BL/6J Murine model of CMV...
4.
Zhao J, Yang Y, You S, Jing Z, Wu Y, Cheng J, et al.
Coron Artery Dis . 2006 Jul; 17(5):463-9. PMID: 16845255
Background: Both fosinopril and valsartan are effective in protecting endothelial function. We hypothesized that they may also reduce myocardial no-reflow. In addition, suppression of adenosine triphosphate-sensitive K (KATP) channel opening...
5.
Wu J, Meng X, Chen Y, Cheng J, Li D, Lu H
Zhonghua Gan Zang Bing Za Zhi . 2003 May; 11(5):315-7. PMID: 12773256
No abstract available.
6.
Wei H, Lu H, Li D, Zhan Y, Wang Z, Huang X, et al.
World J Gastroenterol . 2002 Jan; 6(6):824-828. PMID: 11819703
AIM:To assess the effect of ACE inhibitor and Ang II type 1 (AT1) receptor antagonist in preventing hepatic fibrosis caused by CCl(4) administration in rats;to investigate whether or not there...
7.
Wei H, Li D, Lu H, Zhan Y, Wang Z, Huang X, et al.
World J Gastroenterol . 2002 Jan; 6(4):540-545. PMID: 11819643
AIM:To investigate effect of losartan, an AT1 receptor antagonist, on hepatic fibrosis induced by CCl(4); and to determine whether or not AT1 receptors are expressed on hepatic stellate cells. METHODS...